Sangamo Therapeutics, Inc.
Sangamo Therapeutics, Inc. (SGMO) Stock Competitors & Peer Comparison
See (SGMO) competitors and their performances in Stock Market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| SGMO | $0.26 | -1.12% | 105.6M | -0.58 | -$0.44 | N/A |
| VRTX | $435.10 | -0.59% | 110.7B | 28.40 | $15.32 | N/A |
| REGN | $766.02 | +2.60% | 79.6B | 18.47 | $41.48 | +0.47% |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| ARGX | $787.95 | -0.66% | 48.7B | 40.17 | $19.61 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| ALNY | $313.79 | +1.03% | 41.9B | 134.10 | $2.34 | N/A |
| INSM | $143.83 | -0.45% | 31B | -22.37 | -$6.43 | N/A |
| RVMD | $134.48 | -4.96% | 28.1B | -22.56 | -$5.96 | N/A |
| BNTX | $105.56 | -2.80% | 26.5B | -19.02 | -$5.55 | N/A |
Stock Comparison
SGMO vs VRTX Comparison April 2026
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 105.6M. In comparison, VRTX has a market cap of 110.7B. Regarding current trading prices, SGMO is priced at $0.26, while VRTX trades at $435.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.58, whereas VRTX's P/E ratio is 28.40. In terms of profitability, SGMO's ROE is -29.83%, compared to VRTX's ROE of +0.23%. Regarding short-term risk, SGMO is more volatile compared to VRTX. This indicates potentially higher risk in terms of short-term price fluctuations for SGMO.Check VRTX's competition here
SGMO vs REGN Comparison April 2026
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 105.6M. In comparison, REGN has a market cap of 79.6B. Regarding current trading prices, SGMO is priced at $0.26, while REGN trades at $766.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.58, whereas REGN's P/E ratio is 18.47. In terms of profitability, SGMO's ROE is -29.83%, compared to REGN's ROE of +0.15%. Regarding short-term risk, SGMO is more volatile compared to REGN. This indicates potentially higher risk in terms of short-term price fluctuations for SGMO.Check REGN's competition here
SGMO vs VRNA Comparison April 2026
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 105.6M. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, SGMO is priced at $0.26, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.58, whereas VRNA's P/E ratio is -102.80. In terms of profitability, SGMO's ROE is -29.83%, compared to VRNA's ROE of -0.13%. Regarding short-term risk, SGMO is more volatile compared to VRNA. This indicates potentially higher risk in terms of short-term price fluctuations for SGMO.Check VRNA's competition here
SGMO vs ARGX Comparison April 2026
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 105.6M. In comparison, ARGX has a market cap of 48.7B. Regarding current trading prices, SGMO is priced at $0.26, while ARGX trades at $787.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.58, whereas ARGX's P/E ratio is 40.17. In terms of profitability, SGMO's ROE is -29.83%, compared to ARGX's ROE of +0.34%. Regarding short-term risk, SGMO is more volatile compared to ARGX. This indicates potentially higher risk in terms of short-term price fluctuations for SGMO.Check ARGX's competition here
SGMO vs SGEN Comparison April 2026
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 105.6M. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, SGMO is priced at $0.26, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.58, whereas SGEN's P/E ratio is -57.19. In terms of profitability, SGMO's ROE is -29.83%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, SGMO is more volatile compared to SGEN. This indicates potentially higher risk in terms of short-term price fluctuations for SGMO.Check SGEN's competition here
SGMO vs ALNY Comparison April 2026
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 105.6M. In comparison, ALNY has a market cap of 41.9B. Regarding current trading prices, SGMO is priced at $0.26, while ALNY trades at $313.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.58, whereas ALNY's P/E ratio is 134.10. In terms of profitability, SGMO's ROE is -29.83%, compared to ALNY's ROE of +0.90%. Regarding short-term risk, SGMO is more volatile compared to ALNY. This indicates potentially higher risk in terms of short-term price fluctuations for SGMO.Check ALNY's competition here
SGMO vs INSM Comparison April 2026
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 105.6M. In comparison, INSM has a market cap of 31B. Regarding current trading prices, SGMO is priced at $0.26, while INSM trades at $143.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.58, whereas INSM's P/E ratio is -22.37. In terms of profitability, SGMO's ROE is -29.83%, compared to INSM's ROE of -1.68%. Regarding short-term risk, SGMO is more volatile compared to INSM. This indicates potentially higher risk in terms of short-term price fluctuations for SGMO.Check INSM's competition here
SGMO vs RVMD Comparison April 2026
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 105.6M. In comparison, RVMD has a market cap of 28.1B. Regarding current trading prices, SGMO is priced at $0.26, while RVMD trades at $134.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.58, whereas RVMD's P/E ratio is -22.56. In terms of profitability, SGMO's ROE is -29.83%, compared to RVMD's ROE of -0.63%. Regarding short-term risk, SGMO is less volatile compared to RVMD. This indicates potentially lower risk in terms of short-term price fluctuations for SGMO.Check RVMD's competition here
SGMO vs BNTX Comparison April 2026
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 105.6M. In comparison, BNTX has a market cap of 26.5B. Regarding current trading prices, SGMO is priced at $0.26, while BNTX trades at $105.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.58, whereas BNTX's P/E ratio is -19.02. In terms of profitability, SGMO's ROE is -29.83%, compared to BNTX's ROE of -0.06%. Regarding short-term risk, SGMO is more volatile compared to BNTX. This indicates potentially higher risk in terms of short-term price fluctuations for SGMO.Check BNTX's competition here
SGMO vs UTHR Comparison April 2026
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 105.6M. In comparison, UTHR has a market cap of 25.1B. Regarding current trading prices, SGMO is priced at $0.26, while UTHR trades at $572.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.58, whereas UTHR's P/E ratio is 20.55. In terms of profitability, SGMO's ROE is -29.83%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, SGMO is more volatile compared to UTHR. This indicates potentially higher risk in terms of short-term price fluctuations for SGMO.Check UTHR's competition here
SGMO vs RPRX Comparison April 2026
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 105.6M. In comparison, RPRX has a market cap of 21.3B. Regarding current trading prices, SGMO is priced at $0.26, while RPRX trades at $49.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.58, whereas RPRX's P/E ratio is 27.89. In terms of profitability, SGMO's ROE is -29.83%, compared to RPRX's ROE of +0.12%. Regarding short-term risk, SGMO is more volatile compared to RPRX. This indicates potentially higher risk in terms of short-term price fluctuations for SGMO.Check RPRX's competition here
SGMO vs MRNA Comparison April 2026
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 105.6M. In comparison, MRNA has a market cap of 21B. Regarding current trading prices, SGMO is priced at $0.26, while MRNA trades at $52.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.58, whereas MRNA's P/E ratio is -7.28. In terms of profitability, SGMO's ROE is -29.83%, compared to MRNA's ROE of -0.30%. Regarding short-term risk, SGMO is less volatile compared to MRNA. This indicates potentially lower risk in terms of short-term price fluctuations for SGMO.Check MRNA's competition here
SGMO vs BGNE Comparison April 2026
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 105.6M. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, SGMO is priced at $0.26, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.58, whereas BGNE's P/E ratio is -22.55. In terms of profitability, SGMO's ROE is -29.83%, compared to BGNE's ROE of +0.07%. Regarding short-term risk, SGMO is more volatile compared to BGNE. This indicates potentially higher risk in terms of short-term price fluctuations for SGMO.Check BGNE's competition here
SGMO vs ROIV Comparison April 2026
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 105.6M. In comparison, ROIV has a market cap of 20.1B. Regarding current trading prices, SGMO is priced at $0.26, while ROIV trades at $28.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.58, whereas ROIV's P/E ratio is -24.05. In terms of profitability, SGMO's ROE is -29.83%, compared to ROIV's ROE of -0.18%. Regarding short-term risk, SGMO is more volatile compared to ROIV. This indicates potentially higher risk in terms of short-term price fluctuations for SGMO.Check ROIV's competition here
SGMO vs INCY Comparison April 2026
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 105.6M. In comparison, INCY has a market cap of 19B. Regarding current trading prices, SGMO is priced at $0.26, while INCY trades at $95.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.58, whereas INCY's P/E ratio is 14.90. In terms of profitability, SGMO's ROE is -29.83%, compared to INCY's ROE of +0.29%. Regarding short-term risk, SGMO is more volatile compared to INCY. This indicates potentially higher risk in terms of short-term price fluctuations for SGMO.Check INCY's competition here
SGMO vs DNA-WT Comparison April 2026
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 105.6M. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, SGMO is priced at $0.26, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.58, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, SGMO's ROE is -29.83%, compared to DNA-WT's ROE of -0.54%. Regarding short-term risk, SGMO is more volatile compared to DNA-WT. This indicates potentially higher risk in terms of short-term price fluctuations for SGMO.Check DNA-WT's competition here
SGMO vs SMMT Comparison April 2026
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 105.6M. In comparison, SMMT has a market cap of 17.3B. Regarding current trading prices, SGMO is priced at $0.26, while SMMT trades at $22.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.58, whereas SMMT's P/E ratio is -15.47. In terms of profitability, SGMO's ROE is -29.83%, compared to SMMT's ROE of -2.97%. Regarding short-term risk, SGMO is less volatile compared to SMMT. This indicates potentially lower risk in terms of short-term price fluctuations for SGMO.Check SMMT's competition here
SGMO vs GMAB Comparison April 2026
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 105.6M. In comparison, GMAB has a market cap of 16.6B. Regarding current trading prices, SGMO is priced at $0.26, while GMAB trades at $26.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.58, whereas GMAB's P/E ratio is 17.52. In terms of profitability, SGMO's ROE is -29.83%, compared to GMAB's ROE of +0.14%. Regarding short-term risk, SGMO is more volatile compared to GMAB. This indicates potentially higher risk in terms of short-term price fluctuations for SGMO.Check GMAB's competition here
SGMO vs BBIO Comparison April 2026
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 105.6M. In comparison, BBIO has a market cap of 13.9B. Regarding current trading prices, SGMO is priced at $0.26, while BBIO trades at $71.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.58, whereas BBIO's P/E ratio is -18.96. In terms of profitability, SGMO's ROE is -29.83%, compared to BBIO's ROE of +0.39%. Regarding short-term risk, SGMO is more volatile compared to BBIO. This indicates potentially higher risk in terms of short-term price fluctuations for SGMO.Check BBIO's competition here
SGMO vs ASND Comparison April 2026
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 105.6M. In comparison, ASND has a market cap of 13.8B. Regarding current trading prices, SGMO is priced at $0.26, while ASND trades at $225.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.58, whereas ASND's P/E ratio is -50.56. In terms of profitability, SGMO's ROE is -29.83%, compared to ASND's ROE of +1.28%. Regarding short-term risk, SGMO is more volatile compared to ASND. This indicates potentially higher risk in terms of short-term price fluctuations for SGMO.Check ASND's competition here
SGMO vs KRTX Comparison April 2026
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 105.6M. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, SGMO is priced at $0.26, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.58, whereas KRTX's P/E ratio is -28.09. In terms of profitability, SGMO's ROE is -29.83%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, SGMO is more volatile compared to KRTX. This indicates potentially higher risk in terms of short-term price fluctuations for SGMO.Check KRTX's competition here
SGMO vs JAZZ Comparison April 2026
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 105.6M. In comparison, JAZZ has a market cap of 12.3B. Regarding current trading prices, SGMO is priced at $0.26, while JAZZ trades at $199.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.58, whereas JAZZ's P/E ratio is -34.23. In terms of profitability, SGMO's ROE is -29.83%, compared to JAZZ's ROE of -0.09%. Regarding short-term risk, SGMO is more volatile compared to JAZZ. This indicates potentially higher risk in terms of short-term price fluctuations for SGMO.Check JAZZ's competition here
SGMO vs IONS Comparison April 2026
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 105.6M. In comparison, IONS has a market cap of 12.2B. Regarding current trading prices, SGMO is priced at $0.26, while IONS trades at $74.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.58, whereas IONS's P/E ratio is -31.13. In terms of profitability, SGMO's ROE is -29.83%, compared to IONS's ROE of -0.69%. Regarding short-term risk, SGMO is more volatile compared to IONS. This indicates potentially higher risk in terms of short-term price fluctuations for SGMO.Check IONS's competition here
SGMO vs EXEL Comparison April 2026
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 105.6M. In comparison, EXEL has a market cap of 12B. Regarding current trading prices, SGMO is priced at $0.26, while EXEL trades at $46.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.58, whereas EXEL's P/E ratio is 16.56. In terms of profitability, SGMO's ROE is -29.83%, compared to EXEL's ROE of +0.37%. Regarding short-term risk, SGMO is more volatile compared to EXEL. This indicates potentially higher risk in terms of short-term price fluctuations for SGMO.Check EXEL's competition here
SGMO vs MDGL Comparison April 2026
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 105.6M. In comparison, MDGL has a market cap of 11.9B. Regarding current trading prices, SGMO is priced at $0.26, while MDGL trades at $518.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.58, whereas MDGL's P/E ratio is -40.34. In terms of profitability, SGMO's ROE is -29.83%, compared to MDGL's ROE of -0.44%. Regarding short-term risk, SGMO is more volatile compared to MDGL. This indicates potentially higher risk in terms of short-term price fluctuations for SGMO.Check MDGL's competition here
SGMO vs RNAM Comparison April 2026
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 105.6M. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, SGMO is priced at $0.26, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.58, whereas RNAM's P/E ratio is -17.39. In terms of profitability, SGMO's ROE is -29.83%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, SGMO is more volatile compared to RNAM. This indicates potentially higher risk in terms of short-term price fluctuations for SGMO.Check RNAM's competition here
SGMO vs ARWR Comparison April 2026
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 105.6M. In comparison, ARWR has a market cap of 10.4B. Regarding current trading prices, SGMO is priced at $0.26, while ARWR trades at $74.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.58, whereas ARWR's P/E ratio is 46.50. In terms of profitability, SGMO's ROE is -29.83%, compared to ARWR's ROE of +0.36%. Regarding short-term risk, SGMO is more volatile compared to ARWR. This indicates potentially higher risk in terms of short-term price fluctuations for SGMO.Check ARWR's competition here
SGMO vs BMRN Comparison April 2026
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 105.6M. In comparison, BMRN has a market cap of 10.4B. Regarding current trading prices, SGMO is priced at $0.26, while BMRN trades at $53.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.58, whereas BMRN's P/E ratio is 30.01. In terms of profitability, SGMO's ROE is -29.83%, compared to BMRN's ROE of +0.06%. Regarding short-term risk, SGMO is more volatile compared to BMRN. This indicates potentially higher risk in terms of short-term price fluctuations for SGMO.Check BMRN's competition here
SGMO vs RXDX Comparison April 2026
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 105.6M. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, SGMO is priced at $0.26, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.58, whereas RXDX's P/E ratio is -56.47. In terms of profitability, SGMO's ROE is -29.83%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, SGMO is more volatile compared to RXDX. This indicates potentially higher risk in terms of short-term price fluctuations for SGMO.Check RXDX's competition here
SGMO vs AXSM Comparison April 2026
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 105.6M. In comparison, AXSM has a market cap of 9.3B. Regarding current trading prices, SGMO is priced at $0.26, while AXSM trades at $182.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.58, whereas AXSM's P/E ratio is -49.48. In terms of profitability, SGMO's ROE is -29.83%, compared to AXSM's ROE of -2.54%. Regarding short-term risk, SGMO is more volatile compared to AXSM. This indicates potentially higher risk in terms of short-term price fluctuations for SGMO.Check AXSM's competition here
SGMO vs PCVX Comparison April 2026
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 105.6M. In comparison, PCVX has a market cap of 8.7B. Regarding current trading prices, SGMO is priced at $0.26, while PCVX trades at $60.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.58, whereas PCVX's P/E ratio is -10.79. In terms of profitability, SGMO's ROE is -29.83%, compared to PCVX's ROE of -0.26%. Regarding short-term risk, SGMO is more volatile compared to PCVX. This indicates potentially higher risk in terms of short-term price fluctuations for SGMO.Check PCVX's competition here
SGMO vs IMGN Comparison April 2026
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 105.6M. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, SGMO is priced at $0.26, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.58, whereas IMGN's P/E ratio is -111.55. In terms of profitability, SGMO's ROE is -29.83%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, SGMO is more volatile compared to IMGN. This indicates potentially higher risk in terms of short-term price fluctuations for SGMO.Check IMGN's competition here
SGMO vs IBRX Comparison April 2026
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 105.6M. In comparison, IBRX has a market cap of 8.4B. Regarding current trading prices, SGMO is priced at $0.26, while IBRX trades at $8.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.58, whereas IBRX's P/E ratio is -21.58. In terms of profitability, SGMO's ROE is -29.83%, compared to IBRX's ROE of +0.64%. Regarding short-term risk, SGMO is more volatile compared to IBRX. This indicates potentially higher risk in terms of short-term price fluctuations for SGMO.Check IBRX's competition here
SGMO vs BPMC Comparison April 2026
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 105.6M. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, SGMO is priced at $0.26, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.58, whereas BPMC's P/E ratio is -51.58. In terms of profitability, SGMO's ROE is -29.83%, compared to BPMC's ROE of -0.15%. Regarding short-term risk, SGMO is more volatile compared to BPMC. This indicates potentially higher risk in terms of short-term price fluctuations for SGMO.Check BPMC's competition here
SGMO vs CERE Comparison April 2026
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 105.6M. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, SGMO is priced at $0.26, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.58, whereas CERE's P/E ratio is -16.47. In terms of profitability, SGMO's ROE is -29.83%, compared to CERE's ROE of -0.72%. Regarding short-term risk, SGMO is more volatile compared to CERE. This indicates potentially higher risk in terms of short-term price fluctuations for SGMO.Check CERE's competition here
SGMO vs TECH Comparison April 2026
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 105.6M. In comparison, TECH has a market cap of 8.2B. Regarding current trading prices, SGMO is priced at $0.26, while TECH trades at $52.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.58, whereas TECH's P/E ratio is 98.49. In terms of profitability, SGMO's ROE is -29.83%, compared to TECH's ROE of +0.04%. Regarding short-term risk, SGMO is less volatile compared to TECH. This indicates potentially lower risk in terms of short-term price fluctuations for SGMO.Check TECH's competition here
SGMO vs CYTK Comparison April 2026
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 105.6M. In comparison, CYTK has a market cap of 8.1B. Regarding current trading prices, SGMO is priced at $0.26, while CYTK trades at $65.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.58, whereas CYTK's P/E ratio is -10.01. In terms of profitability, SGMO's ROE is -29.83%, compared to CYTK's ROE of +1.73%. Regarding short-term risk, SGMO is more volatile compared to CYTK. This indicates potentially higher risk in terms of short-term price fluctuations for SGMO.Check CYTK's competition here
SGMO vs NUVL Comparison April 2026
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 105.6M. In comparison, NUVL has a market cap of 7.9B. Regarding current trading prices, SGMO is priced at $0.26, while NUVL trades at $108.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.58, whereas NUVL's P/E ratio is -18.47. In terms of profitability, SGMO's ROE is -29.83%, compared to NUVL's ROE of -0.42%. Regarding short-term risk, SGMO is more volatile compared to NUVL. This indicates potentially higher risk in terms of short-term price fluctuations for SGMO.Check NUVL's competition here
SGMO vs KRYS Comparison April 2026
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 105.6M. In comparison, KRYS has a market cap of 7.9B. Regarding current trading prices, SGMO is priced at $0.26, while KRYS trades at $268.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.58, whereas KRYS's P/E ratio is 39.13. In terms of profitability, SGMO's ROE is -29.83%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, SGMO is more volatile compared to KRYS. This indicates potentially higher risk in terms of short-term price fluctuations for SGMO.Check KRYS's competition here
SGMO vs HALO Comparison April 2026
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 105.6M. In comparison, HALO has a market cap of 7.9B. Regarding current trading prices, SGMO is priced at $0.26, while HALO trades at $66.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.58, whereas HALO's P/E ratio is 26.01. In terms of profitability, SGMO's ROE is -29.83%, compared to HALO's ROE of +0.93%. Regarding short-term risk, SGMO is more volatile compared to HALO. This indicates potentially higher risk in terms of short-term price fluctuations for SGMO.Check HALO's competition here
SGMO vs MTSR Comparison April 2026
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 105.6M. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, SGMO is priced at $0.26, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.58, whereas MTSR's P/E ratio is -23.58. In terms of profitability, SGMO's ROE is -29.83%, compared to MTSR's ROE of -0.80%. Regarding short-term risk, SGMO is more volatile compared to MTSR. This indicates potentially higher risk in terms of short-term price fluctuations for SGMO.Check MTSR's competition here
SGMO vs ABVX Comparison April 2026
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 105.6M. In comparison, ABVX has a market cap of 7.4B. Regarding current trading prices, SGMO is priced at $0.26, while ABVX trades at $113.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.58, whereas ABVX's P/E ratio is -19.81. In terms of profitability, SGMO's ROE is -29.83%, compared to ABVX's ROE of -1.59%. Regarding short-term risk, SGMO is more volatile compared to ABVX. This indicates potentially higher risk in terms of short-term price fluctuations for SGMO.Check ABVX's competition here
SGMO vs KYMR Comparison April 2026
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 105.6M. In comparison, KYMR has a market cap of 7.1B. Regarding current trading prices, SGMO is priced at $0.26, while KYMR trades at $87.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.58, whereas KYMR's P/E ratio is -23.62. In terms of profitability, SGMO's ROE is -29.83%, compared to KYMR's ROE of -0.29%. Regarding short-term risk, SGMO is more volatile compared to KYMR. This indicates potentially higher risk in terms of short-term price fluctuations for SGMO.Check KYMR's competition here
SGMO vs ERAS Comparison April 2026
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 105.6M. In comparison, ERAS has a market cap of 7B. Regarding current trading prices, SGMO is priced at $0.26, while ERAS trades at $22.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.58, whereas ERAS's P/E ratio is -51.07. In terms of profitability, SGMO's ROE is -29.83%, compared to ERAS's ROE of -0.34%. Regarding short-term risk, SGMO is less volatile compared to ERAS. This indicates potentially lower risk in terms of short-term price fluctuations for SGMO.Check ERAS's competition here
SGMO vs PRAX Comparison April 2026
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 105.6M. In comparison, PRAX has a market cap of 7B. Regarding current trading prices, SGMO is priced at $0.26, while PRAX trades at $329.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.58, whereas PRAX's P/E ratio is -24.45. In terms of profitability, SGMO's ROE is -29.83%, compared to PRAX's ROE of -0.59%. Regarding short-term risk, SGMO is more volatile compared to PRAX. This indicates potentially higher risk in terms of short-term price fluctuations for SGMO.Check PRAX's competition here
SGMO vs MRUS Comparison April 2026
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 105.6M. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, SGMO is priced at $0.26, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.58, whereas MRUS's P/E ratio is -17.05. In terms of profitability, SGMO's ROE is -29.83%, compared to MRUS's ROE of -0.51%. Regarding short-term risk, SGMO is more volatile compared to MRUS. This indicates potentially higher risk in terms of short-term price fluctuations for SGMO.Check MRUS's competition here
SGMO vs ACLX Comparison April 2026
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 105.6M. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, SGMO is priced at $0.26, while ACLX trades at $115.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.58, whereas ACLX's P/E ratio is -28.27. In terms of profitability, SGMO's ROE is -29.83%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, SGMO is more volatile compared to ACLX. This indicates potentially higher risk in terms of short-term price fluctuations for SGMO.Check ACLX's competition here
SGMO vs BLTE Comparison April 2026
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 105.6M. In comparison, BLTE has a market cap of 6.6B. Regarding current trading prices, SGMO is priced at $0.26, while BLTE trades at $164.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.58, whereas BLTE's P/E ratio is -70.88. In terms of profitability, SGMO's ROE is -29.83%, compared to BLTE's ROE of -0.23%. Regarding short-term risk, SGMO is more volatile compared to BLTE. This indicates potentially higher risk in terms of short-term price fluctuations for SGMO.Check BLTE's competition here
SGMO vs RETA Comparison April 2026
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 105.6M. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, SGMO is priced at $0.26, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.58, whereas RETA's P/E ratio is -66.29. In terms of profitability, SGMO's ROE is -29.83%, compared to RETA's ROE of +0.47%. Regarding short-term risk, SGMO is more volatile compared to RETA. This indicates potentially higher risk in terms of short-term price fluctuations for SGMO.Check RETA's competition here
SGMO vs PTGX Comparison April 2026
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 105.6M. In comparison, PTGX has a market cap of 6.5B. Regarding current trading prices, SGMO is priced at $0.26, while PTGX trades at $102.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.58, whereas PTGX's P/E ratio is -50.06. In terms of profitability, SGMO's ROE is -29.83%, compared to PTGX's ROE of -0.20%. Regarding short-term risk, SGMO is more volatile compared to PTGX. This indicates potentially higher risk in terms of short-term price fluctuations for SGMO.Check PTGX's competition here
SGMO vs CGON Comparison April 2026
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 105.6M. In comparison, CGON has a market cap of 5.9B. Regarding current trading prices, SGMO is priced at $0.26, while CGON trades at $69.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.58, whereas CGON's P/E ratio is -33.60. In terms of profitability, SGMO's ROE is -29.83%, compared to CGON's ROE of -0.23%. Regarding short-term risk, SGMO is less volatile compared to CGON. This indicates potentially lower risk in terms of short-term price fluctuations for SGMO.Check CGON's competition here
SGMO vs TGTX Comparison April 2026
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 105.6M. In comparison, TGTX has a market cap of 5.9B. Regarding current trading prices, SGMO is priced at $0.26, while TGTX trades at $36.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.58, whereas TGTX's P/E ratio is 13.33. In terms of profitability, SGMO's ROE is -29.83%, compared to TGTX's ROE of +1.01%. Regarding short-term risk, SGMO is more volatile compared to TGTX. This indicates potentially higher risk in terms of short-term price fluctuations for SGMO.Check TGTX's competition here
SGMO vs IMVT Comparison April 2026
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 105.6M. In comparison, IMVT has a market cap of 5.9B. Regarding current trading prices, SGMO is priced at $0.26, while IMVT trades at $28.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.58, whereas IMVT's P/E ratio is -10.83. In terms of profitability, SGMO's ROE is -29.83%, compared to IMVT's ROE of -0.66%. Regarding short-term risk, SGMO is more volatile compared to IMVT. This indicates potentially higher risk in terms of short-term price fluctuations for SGMO.Check IMVT's competition here
SGMO vs CNTA Comparison April 2026
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 105.6M. In comparison, CNTA has a market cap of 5.9B. Regarding current trading prices, SGMO is priced at $0.26, while CNTA trades at $39.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.58, whereas CNTA's P/E ratio is -27.01. In terms of profitability, SGMO's ROE is -29.83%, compared to CNTA's ROE of -0.51%. Regarding short-term risk, SGMO is more volatile compared to CNTA. This indicates potentially higher risk in terms of short-term price fluctuations for SGMO.Check CNTA's competition here
SGMO vs COGT Comparison April 2026
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 105.6M. In comparison, COGT has a market cap of 5.9B. Regarding current trading prices, SGMO is priced at $0.26, while COGT trades at $36.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.58, whereas COGT's P/E ratio is -16.73. In terms of profitability, SGMO's ROE is -29.83%, compared to COGT's ROE of -1.00%. Regarding short-term risk, SGMO is more volatile compared to COGT. This indicates potentially higher risk in terms of short-term price fluctuations for SGMO.Check COGT's competition here
SGMO vs RYTM Comparison April 2026
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 105.6M. In comparison, RYTM has a market cap of 5.8B. Regarding current trading prices, SGMO is priced at $0.26, while RYTM trades at $85.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.58, whereas RYTM's P/E ratio is -27.39. In terms of profitability, SGMO's ROE is -29.83%, compared to RYTM's ROE of -1.79%. Regarding short-term risk, SGMO is more volatile compared to RYTM. This indicates potentially higher risk in terms of short-term price fluctuations for SGMO.Check RYTM's competition here
SGMO vs PTCT Comparison April 2026
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 105.6M. In comparison, PTCT has a market cap of 5.7B. Regarding current trading prices, SGMO is priced at $0.26, while PTCT trades at $68.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.58, whereas PTCT's P/E ratio is 7.99. In terms of profitability, SGMO's ROE is -29.83%, compared to PTCT's ROE of -3.62%. Regarding short-term risk, SGMO is more volatile compared to PTCT. This indicates potentially higher risk in terms of short-term price fluctuations for SGMO.Check PTCT's competition here
SGMO vs ALKS Comparison April 2026
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 105.6M. In comparison, ALKS has a market cap of 5.7B. Regarding current trading prices, SGMO is priced at $0.26, while ALKS trades at $33.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.58, whereas ALKS's P/E ratio is 23.72. In terms of profitability, SGMO's ROE is -29.83%, compared to ALKS's ROE of +0.14%. Regarding short-term risk, SGMO is more volatile compared to ALKS. This indicates potentially higher risk in terms of short-term price fluctuations for SGMO.Check ALKS's competition here
SGMO vs CDTX Comparison April 2026
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 105.6M. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, SGMO is priced at $0.26, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.58, whereas CDTX's P/E ratio is -19.77. In terms of profitability, SGMO's ROE is -29.83%, compared to CDTX's ROE of -0.60%. Regarding short-term risk, SGMO is more volatile compared to CDTX. This indicates potentially higher risk in terms of short-term price fluctuations for SGMO.Check CDTX's competition here
SGMO vs CAI Comparison April 2026
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 105.6M. In comparison, CAI has a market cap of 5.6B. Regarding current trading prices, SGMO is priced at $0.26, while CAI trades at $19.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.58, whereas CAI's P/E ratio is -6.15. In terms of profitability, SGMO's ROE is -29.83%, compared to CAI's ROE of +0.25%. Regarding short-term risk, SGMO is less volatile compared to CAI. This indicates potentially lower risk in terms of short-term price fluctuations for SGMO.Check CAI's competition here
SGMO vs ABCM Comparison April 2026
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 105.6M. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, SGMO is priced at $0.26, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.58, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, SGMO's ROE is -29.83%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, SGMO is more volatile compared to ABCM. This indicates potentially higher risk in terms of short-term price fluctuations for SGMO.Check ABCM's competition here
SGMO vs ISEE Comparison April 2026
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 105.6M. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, SGMO is priced at $0.26, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.58, whereas ISEE's P/E ratio is -22.44. In terms of profitability, SGMO's ROE is -29.83%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, SGMO is more volatile compared to ISEE. This indicates potentially higher risk in terms of short-term price fluctuations for SGMO.Check ISEE's competition here
SGMO vs CELC Comparison April 2026
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 105.6M. In comparison, CELC has a market cap of 5.5B. Regarding current trading prices, SGMO is priced at $0.26, while CELC trades at $113.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.58, whereas CELC's P/E ratio is -29.95. In terms of profitability, SGMO's ROE is -29.83%, compared to CELC's ROE of -2.03%. Regarding short-term risk, SGMO is less volatile compared to CELC. This indicates potentially lower risk in terms of short-term price fluctuations for SGMO.Check CELC's competition here
SGMO vs SRRK Comparison April 2026
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 105.6M. In comparison, SRRK has a market cap of 5.5B. Regarding current trading prices, SGMO is priced at $0.26, while SRRK trades at $47.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.58, whereas SRRK's P/E ratio is -14.43. In terms of profitability, SGMO's ROE is -29.83%, compared to SRRK's ROE of -1.46%. Regarding short-term risk, SGMO is more volatile compared to SRRK. This indicates potentially higher risk in terms of short-term price fluctuations for SGMO.Check SRRK's competition here
SGMO vs CRSP Comparison April 2026
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 105.6M. In comparison, CRSP has a market cap of 5.3B. Regarding current trading prices, SGMO is priced at $0.26, while CRSP trades at $55.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.58, whereas CRSP's P/E ratio is -8.53. In terms of profitability, SGMO's ROE is -29.83%, compared to CRSP's ROE of -0.32%. Regarding short-term risk, SGMO is more volatile compared to CRSP. This indicates potentially higher risk in terms of short-term price fluctuations for SGMO.Check CRSP's competition here
SGMO vs APLS Comparison April 2026
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 105.6M. In comparison, APLS has a market cap of 5.2B. Regarding current trading prices, SGMO is priced at $0.26, while APLS trades at $40.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.58, whereas APLS's P/E ratio is 227.44. In terms of profitability, SGMO's ROE is -29.83%, compared to APLS's ROE of +0.08%. Regarding short-term risk, SGMO is more volatile compared to APLS. This indicates potentially higher risk in terms of short-term price fluctuations for SGMO.Check APLS's competition here
SGMO vs FBIOX Comparison April 2026
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 105.6M. In comparison, FBIOX has a market cap of 5.2B. Regarding current trading prices, SGMO is priced at $0.26, while FBIOX trades at $25.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.58, whereas FBIOX's P/E ratio is N/A. In terms of profitability, SGMO's ROE is -29.83%, compared to FBIOX's ROE of +0.00%. Regarding short-term risk, SGMO is more volatile compared to FBIOX. This indicates potentially higher risk in terms of short-term price fluctuations for SGMO.Check FBIOX's competition here
SGMO vs APGE Comparison April 2026
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 105.6M. In comparison, APGE has a market cap of 4.9B. Regarding current trading prices, SGMO is priced at $0.26, while APGE trades at $88.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.58, whereas APGE's P/E ratio is -20.92. In terms of profitability, SGMO's ROE is -29.83%, compared to APGE's ROE of -0.37%. Regarding short-term risk, SGMO is more volatile compared to APGE. This indicates potentially higher risk in terms of short-term price fluctuations for SGMO.Check APGE's competition here
SGMO vs CORT Comparison April 2026
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 105.6M. In comparison, CORT has a market cap of 4.8B. Regarding current trading prices, SGMO is priced at $0.26, while CORT trades at $45.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.58, whereas CORT's P/E ratio is 54.98. In terms of profitability, SGMO's ROE is -29.83%, compared to CORT's ROE of +0.15%. Regarding short-term risk, SGMO is less volatile compared to CORT. This indicates potentially lower risk in terms of short-term price fluctuations for SGMO.Check CORT's competition here
SGMO vs TERN Comparison April 2026
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 105.6M. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, SGMO is priced at $0.26, while TERN trades at $52.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.58, whereas TERN's P/E ratio is -51.29. In terms of profitability, SGMO's ROE is -29.83%, compared to TERN's ROE of -0.20%. Regarding short-term risk, SGMO is more volatile compared to TERN. This indicates potentially higher risk in terms of short-term price fluctuations for SGMO.Check TERN's competition here
SGMO vs MIRM Comparison April 2026
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 105.6M. In comparison, MIRM has a market cap of 4.6B. Regarding current trading prices, SGMO is priced at $0.26, while MIRM trades at $91.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.58, whereas MIRM's P/E ratio is -195.68. In terms of profitability, SGMO's ROE is -29.83%, compared to MIRM's ROE of -0.09%. Regarding short-term risk, SGMO is more volatile compared to MIRM. This indicates potentially higher risk in terms of short-term price fluctuations for SGMO.Check MIRM's competition here
SGMO vs LGND Comparison April 2026
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 105.6M. In comparison, LGND has a market cap of 4.6B. Regarding current trading prices, SGMO is priced at $0.26, while LGND trades at $228.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.58, whereas LGND's P/E ratio is 37.26. In terms of profitability, SGMO's ROE is -29.83%, compared to LGND's ROE of +0.14%. Regarding short-term risk, SGMO is more volatile compared to LGND. This indicates potentially higher risk in terms of short-term price fluctuations for SGMO.Check LGND's competition here
SGMO vs FOLD Comparison April 2026
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 105.6M. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, SGMO is priced at $0.26, while FOLD trades at $14.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.58, whereas FOLD's P/E ratio is -160.67. In terms of profitability, SGMO's ROE is -29.83%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, SGMO is more volatile compared to FOLD. This indicates potentially higher risk in terms of short-term price fluctuations for SGMO.Check FOLD's competition here
SGMO vs AKRO Comparison April 2026
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 105.6M. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, SGMO is priced at $0.26, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.58, whereas AKRO's P/E ratio is -14.57. In terms of profitability, SGMO's ROE is -29.83%, compared to AKRO's ROE of -0.31%. Regarding short-term risk, SGMO is more volatile compared to AKRO. This indicates potentially higher risk in terms of short-term price fluctuations for SGMO.Check AKRO's competition here
SGMO vs ALPN Comparison April 2026
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 105.6M. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, SGMO is priced at $0.26, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.58, whereas ALPN's P/E ratio is -101.52. In terms of profitability, SGMO's ROE is -29.83%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, SGMO is more volatile compared to ALPN. This indicates potentially higher risk in terms of short-term price fluctuations for SGMO.Check ALPN's competition here
SGMO vs LEGN Comparison April 2026
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 105.6M. In comparison, LEGN has a market cap of 4.4B. Regarding current trading prices, SGMO is priced at $0.26, while LEGN trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.58, whereas LEGN's P/E ratio is -14.81. In terms of profitability, SGMO's ROE is -29.83%, compared to LEGN's ROE of -0.29%. Regarding short-term risk, SGMO is less volatile compared to LEGN. This indicates potentially lower risk in terms of short-term price fluctuations for SGMO.Check LEGN's competition here
SGMO vs XENE Comparison April 2026
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 105.6M. In comparison, XENE has a market cap of 4.4B. Regarding current trading prices, SGMO is priced at $0.26, while XENE trades at $55.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.58, whereas XENE's P/E ratio is -12.70. In terms of profitability, SGMO's ROE is -29.83%, compared to XENE's ROE of -0.56%. Regarding short-term risk, SGMO is more volatile compared to XENE. This indicates potentially higher risk in terms of short-term price fluctuations for SGMO.Check XENE's competition here
SGMO vs OPT Comparison April 2026
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 105.6M. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, SGMO is priced at $0.26, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.58, whereas OPT's P/E ratio is -1.52. In terms of profitability, SGMO's ROE is -29.83%, compared to OPT's ROE of +0.88%. Regarding short-term risk, SGMO is more volatile compared to OPT. This indicates potentially higher risk in terms of short-term price fluctuations for SGMO.Check OPT's competition here
SGMO vs SYRE Comparison April 2026
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 105.6M. In comparison, SYRE has a market cap of 4.2B. Regarding current trading prices, SGMO is priced at $0.26, while SYRE trades at $69.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.58, whereas SYRE's P/E ratio is -34.97. In terms of profitability, SGMO's ROE is -29.83%, compared to SYRE's ROE of -0.29%. Regarding short-term risk, SGMO is less volatile compared to SYRE. This indicates potentially lower risk in terms of short-term price fluctuations for SGMO.Check SYRE's competition here
SGMO vs MRTX Comparison April 2026
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 105.6M. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, SGMO is priced at $0.26, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.58, whereas MRTX's P/E ratio is -4.82. In terms of profitability, SGMO's ROE is -29.83%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, SGMO is more volatile compared to MRTX. This indicates potentially higher risk in terms of short-term price fluctuations for SGMO.Check MRTX's competition here
SGMO vs CRNX Comparison April 2026
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 105.6M. In comparison, CRNX has a market cap of 4B. Regarding current trading prices, SGMO is priced at $0.26, while CRNX trades at $38.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.58, whereas CRNX's P/E ratio is -7.78. In terms of profitability, SGMO's ROE is -29.83%, compared to CRNX's ROE of -0.41%. Regarding short-term risk, SGMO is more volatile compared to CRNX. This indicates potentially higher risk in terms of short-term price fluctuations for SGMO.Check CRNX's competition here
SGMO vs VKTX Comparison April 2026
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 105.6M. In comparison, VKTX has a market cap of 3.8B. Regarding current trading prices, SGMO is priced at $0.26, while VKTX trades at $32.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.58, whereas VKTX's P/E ratio is -10.28. In terms of profitability, SGMO's ROE is -29.83%, compared to VKTX's ROE of -0.48%. Regarding short-term risk, SGMO is less volatile compared to VKTX. This indicates potentially lower risk in terms of short-term price fluctuations for SGMO.Check VKTX's competition here
SGMO vs ACAD Comparison April 2026
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 105.6M. In comparison, ACAD has a market cap of 3.8B. Regarding current trading prices, SGMO is priced at $0.26, while ACAD trades at $22.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.58, whereas ACAD's P/E ratio is 9.61. In terms of profitability, SGMO's ROE is -29.83%, compared to ACAD's ROE of +0.42%. Regarding short-term risk, SGMO is more volatile compared to ACAD. This indicates potentially higher risk in terms of short-term price fluctuations for SGMO.Check ACAD's competition here
SGMO vs TVTX Comparison April 2026
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 105.6M. In comparison, TVTX has a market cap of 3.8B. Regarding current trading prices, SGMO is priced at $0.26, while TVTX trades at $40.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.58, whereas TVTX's P/E ratio is -71.61. In terms of profitability, SGMO's ROE is -29.83%, compared to TVTX's ROE of -0.79%. Regarding short-term risk, SGMO is more volatile compared to TVTX. This indicates potentially higher risk in terms of short-term price fluctuations for SGMO.Check TVTX's competition here
SGMO vs RYZB Comparison April 2026
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 105.6M. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, SGMO is priced at $0.26, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.58, whereas RYZB's P/E ratio is -57.86. In terms of profitability, SGMO's ROE is -29.83%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, SGMO is more volatile compared to RYZB. This indicates potentially higher risk in terms of short-term price fluctuations for SGMO.Check RYZB's competition here
SGMO vs CBAY Comparison April 2026
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 105.6M. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, SGMO is priced at $0.26, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.58, whereas CBAY's P/E ratio is -32.81. In terms of profitability, SGMO's ROE is -29.83%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, SGMO is more volatile compared to CBAY. This indicates potentially higher risk in terms of short-term price fluctuations for SGMO.Check CBAY's competition here
SGMO vs NAMS Comparison April 2026
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 105.6M. In comparison, NAMS has a market cap of 3.6B. Regarding current trading prices, SGMO is priced at $0.26, while NAMS trades at $31.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.58, whereas NAMS's P/E ratio is -18.29. In terms of profitability, SGMO's ROE is -29.83%, compared to NAMS's ROE of -0.27%. Regarding short-term risk, SGMO is less volatile compared to NAMS. This indicates potentially lower risk in terms of short-term price fluctuations for SGMO.Check NAMS's competition here
SGMO vs SWTX Comparison April 2026
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 105.6M. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, SGMO is priced at $0.26, while SWTX trades at $46.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.58, whereas SWTX's P/E ratio is -13.78. In terms of profitability, SGMO's ROE is -29.83%, compared to SWTX's ROE of -0.36%. Regarding short-term risk, SGMO is more volatile compared to SWTX. This indicates potentially higher risk in terms of short-term price fluctuations for SGMO.Check SWTX's competition here
SGMO vs TLX Comparison April 2026
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 105.6M. In comparison, TLX has a market cap of 3.5B. Regarding current trading prices, SGMO is priced at $0.26, while TLX trades at $10.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.58, whereas TLX's P/E ratio is -509.50. In terms of profitability, SGMO's ROE is -29.83%, compared to TLX's ROE of -0.02%. Regarding short-term risk, SGMO is more volatile compared to TLX. This indicates potentially higher risk in terms of short-term price fluctuations for SGMO.Check TLX's competition here
SGMO vs DNTH Comparison April 2026
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 105.6M. In comparison, DNTH has a market cap of 3.4B. Regarding current trading prices, SGMO is priced at $0.26, while DNTH trades at $89.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.58, whereas DNTH's P/E ratio is -21.37. In terms of profitability, SGMO's ROE is -29.83%, compared to DNTH's ROE of +0.00%. Regarding short-term risk, SGMO is more volatile compared to DNTH. This indicates potentially higher risk in terms of short-term price fluctuations for SGMO.Check DNTH's competition here
SGMO vs CPRX Comparison April 2026
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 105.6M. In comparison, CPRX has a market cap of 3.4B. Regarding current trading prices, SGMO is priced at $0.26, while CPRX trades at $27.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.58, whereas CPRX's P/E ratio is 16.48. In terms of profitability, SGMO's ROE is -29.83%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, SGMO is less volatile compared to CPRX. This indicates potentially lower risk in terms of short-term price fluctuations for SGMO.Check CPRX's competition here
SGMO vs EWTX Comparison April 2026
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 105.6M. In comparison, EWTX has a market cap of 3.4B. Regarding current trading prices, SGMO is priced at $0.26, while EWTX trades at $31.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.58, whereas EWTX's P/E ratio is -19.16. In terms of profitability, SGMO's ROE is -29.83%, compared to EWTX's ROE of -0.32%. Regarding short-term risk, SGMO is more volatile compared to EWTX. This indicates potentially higher risk in terms of short-term price fluctuations for SGMO.Check EWTX's competition here
SGMO vs LQDA Comparison April 2026
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 105.6M. In comparison, LQDA has a market cap of 3.3B. Regarding current trading prices, SGMO is priced at $0.26, while LQDA trades at $37.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.58, whereas LQDA's P/E ratio is -46.82. In terms of profitability, SGMO's ROE is -29.83%, compared to LQDA's ROE of -2.09%. Regarding short-term risk, SGMO is more volatile compared to LQDA. This indicates potentially higher risk in terms of short-term price fluctuations for SGMO.Check LQDA's competition here
SGMO vs ALMS Comparison April 2026
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 105.6M. In comparison, ALMS has a market cap of 3.2B. Regarding current trading prices, SGMO is priced at $0.26, while ALMS trades at $25.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.58, whereas ALMS's P/E ratio is -9.09. In terms of profitability, SGMO's ROE is -29.83%, compared to ALMS's ROE of -0.73%. Regarding short-term risk, SGMO is less volatile compared to ALMS. This indicates potentially lower risk in terms of short-term price fluctuations for SGMO.Check ALMS's competition here
SGMO vs KNSA Comparison April 2026
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 105.6M. In comparison, KNSA has a market cap of 3.2B. Regarding current trading prices, SGMO is priced at $0.26, while KNSA trades at $43.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.58, whereas KNSA's P/E ratio is 57.40. In terms of profitability, SGMO's ROE is -29.83%, compared to KNSA's ROE of +0.11%. Regarding short-term risk, SGMO is more volatile compared to KNSA. This indicates potentially higher risk in terms of short-term price fluctuations for SGMO.Check KNSA's competition here
SGMO vs DYN Comparison April 2026
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 105.6M. In comparison, DYN has a market cap of 3.1B. Regarding current trading prices, SGMO is priced at $0.26, while DYN trades at $18.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.58, whereas DYN's P/E ratio is -5.45. In terms of profitability, SGMO's ROE is -29.83%, compared to DYN's ROE of -0.61%. Regarding short-term risk, SGMO is less volatile compared to DYN. This indicates potentially lower risk in terms of short-term price fluctuations for SGMO.Check DYN's competition here
SGMO vs DNLI Comparison April 2026
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 105.6M. In comparison, DNLI has a market cap of 3.1B. Regarding current trading prices, SGMO is priced at $0.26, while DNLI trades at $19.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.58, whereas DNLI's P/E ratio is -6.55. In terms of profitability, SGMO's ROE is -29.83%, compared to DNLI's ROE of -0.50%. Regarding short-term risk, SGMO is less volatile compared to DNLI. This indicates potentially lower risk in terms of short-term price fluctuations for SGMO.Check DNLI's competition here
SGMO vs BEAM Comparison April 2026
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 105.6M. In comparison, BEAM has a market cap of 3.1B. Regarding current trading prices, SGMO is priced at $0.26, while BEAM trades at $30.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.58, whereas BEAM's P/E ratio is -37.21. In terms of profitability, SGMO's ROE is -29.83%, compared to BEAM's ROE of -0.07%. Regarding short-term risk, SGMO is less volatile compared to BEAM. This indicates potentially lower risk in terms of short-term price fluctuations for SGMO.Check BEAM's competition here
SGMO vs TNGX Comparison April 2026
SGMO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SGMO stands at 105.6M. In comparison, TNGX has a market cap of 3B. Regarding current trading prices, SGMO is priced at $0.26, while TNGX trades at $25.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SGMO currently has a P/E ratio of -0.58, whereas TNGX's P/E ratio is -29.74. In terms of profitability, SGMO's ROE is -29.83%, compared to TNGX's ROE of -0.50%. Regarding short-term risk, SGMO is less volatile compared to TNGX. This indicates potentially lower risk in terms of short-term price fluctuations for SGMO.Check TNGX's competition here